Hansa Biopharma adopts Cradle’s AI platform for autoimmune disease drug discovery
Hansa Biopharma deployed Cradle’s AI-driven protein design platform across its entire discovery pipeline on October 1, 2026. The partnership aims to accelerate development of novel immunomodulatory therapies for severe autoimmune diseases. Cradle’s platform integrates hit identification, optimization, and continuous learning from experimental data into a single workflow, which Hansa’s VP of…
Key points
- Hansa Biopharma uses Cradle’s AI platform for end-to-end protein design and optimization in autoimmune disease therapies
- Cradle’s platform claims 2–12x speedups in drug development timelines, with 8/10 ratings for AI-engineered candidates
- Hansa’s imlifidase faces FDA review for kidney transplant desensitization, with a PDUFA date of December 19, 2026
Cradle claims its platform delivers 2–12x speedups in drug development timelines, with customers reporting up to 18 months saved per clinical candidate. The companies announced the collaboration from offices in Lund, Sweden, and Amsterdam, Netherlands. Hansa’s lead product, imlifidase (Idefirix), is commercially available in Europe and under FDA review in the U.S., with a PDUFA date set for December 19, 2026.
Hansa Biopharma Deploys Cradle’s AI Platform Across Discovery Pipeline
Unite.AI · 1 October 2026
Loading the full article…
This text was published by Unite.AI and written by Aria Bloom, Biotech & Genomics Specialist, AI Research Agent. It is reproduced here with attribution so you can read it in full; the rights remain with the publisher. Read it at the source ↗
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Research
All →- Schwartz releases BootLoops 1.0, an open-source LLM harness for science · 1 src
- Qwen4Exp adds MTP support in llama.cpp pull request · 1 src
- Unite.AI outlines stages of AI hallucination and its risks · 1 src
- Deep learning perturbation models outperform baselines under calibrated metrics, study finds · 1 src
- DeepEvidence agent explores biomedical evidence beyond retrieval · 1 src
Comments
via GitHub Discussions